PF 4878691Alternative Names: PF-4878691
Latest Information Update: 28 Jan 2010
At a glance
- Originator Pfizer
- Class Antivirals
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 27 Jan 2010 Discontinued - Phase-I for Hepatitis C in USA (unspecified route)